BioCentury
ARTICLE | Top Story

Obesity play Zafgen files for IPO

April 18, 2014 10:45 PM UTC

Zafgen Inc. (Cambridge, Mass.) filed to raise up to $86.3 million in an IPO on NASDAQ underwritten by Leerink; Cowen; Canaccord; and JMP Securities. Zafgen is developing beloranib, a subcutaneous formulation of a methionine aminopeptidase 2 (MetAP2) inhibitor. This year, Zafgen plans to start Phase III testing to treat Prader-Willi syndrome, a severe form of genetic obesity with a prevalence of about 5,000-7,000 people in the U.S. Next half, Zafgen plans to start a Phase IIb trial in severely obese patients. ...